Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

NCT03130764 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI Transferred

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

Columbia University